Highlights NexImmune, Inc.

Equities

NEXI

US65344D2080

Delayed Nasdaq Other stock markets 07:55:07 10/05/2024 pm IST			5-day change	1st Jan Change
3.55 ^USD	+2.60%		+6.93%	+59.91%

17/04	North American Morning Briefing : Stock Futures -2-	DJ
16/04	NexImmune, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

NexImmune, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	17/04	CI
North American Morning Briefing : Traders Await -2-	10/04	DJ
NexImmune, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	18/11	CI
NexImmune Extends Partnership With Yale, JDRF for Type 1 Diabetes	24/23/24	MT
NexImmune, Yale, and JDRF Extend Research Partnership for Type 1 Diabetes	24/23/24	CI
NexImmune, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11	CI
Neximmune Announces Initial Positive Data from the NEXI-001 Phase 1 Trial for Relapsed/Refractory Post Allo-Hsct Aml At the American Society of Clinical Oncology 2023 Annual Meeting	05/23/05	CI
NexImmune, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	16/23/16	CI
NEXIMMUNE, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	29/23/29	AQ
NexImmune, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	29/23/29	CI
NEXIMMUNE, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	15/22/15	AQ
NexImmune, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	15/22/15	CI
NexImmune In Collaboration to Assess EBV, HTLV-1 as Therapeutic Targets in Neurological Immune Disease Pathophysiology	06/22/06	MT
NexImmune, Inc. Announces Research Collaboration with National Institute of Neurological Disorders and Stroke of the National Institutes of Health	06/22/06	CI
NextImmune Signs Service Agreement With Selexis to Develop Immunotherapies for Rare Cancers, Autoimmune Disorders	08/22/08	MT
NEXIMMUNE, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	16/22/16	AQ
NexImmune, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	16/22/16	CI
NexImmune Announces IND Clearance by the US FDA for NEXI-003 for the Treatment of HPV-Related Cancers	15/22/15	CI
NEXIMMUNE, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	13/22/13	AQ
NexImmune, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	13/22/13	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights NexImmune, Inc.

Equities

NEXI

US65344D2080

Highlights

Filters